PTC Therapeutics Launches Office at Dubai Science Park

Dubai: PTC Therapeutics, a global biopharmaceutical leader in rare diseases, has launched a Middle East and North Africa (MENA) office at Dubai Science Park to enhance access to transformative medicines for patients with rare diseases in the region. According to Emirates News Agency, the new facility will serve as a regional hub for PTC's MENA operations, focusing on delivering its growing portfolio of treatments to rare disease patients and improving health outcomes. PTC Therapeutics specialises in developing and commercialising therapies for rare diseases globally. It is estimated that around 350 million people worldwide are affected by rare diseases, with approximately 2.8 million known cases in the Middle East region. Zeina Sfeir, Head of MENA, PTC Therapeutics, expressed enthusiasm for the company's expansion, stating, "We are excited to have a physical presence in the region and are looking forward to serve many more patients, across diverse portfolio of therapeutics areas, and with unwavering commit ment." Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of TECOM Group PJSC, highlighted the importance of the collaboration, noting that Dubai Science Park provides a platform for innovative researchers, clinicians, and biological pharmacists. He welcomed PTC Therapeutics as a partner in translating scientific progress into effective therapies, contributing to various Dubai initiatives. For nearly a decade, PTC has established partnerships with regional stakeholders, contributing to the advancement of rare disease treatments in the region. The company has been instrumental in providing transformative treatment for Duchenne Muscular Dystrophy (DMD) and gene therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.